← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Gastric Cancer, Metastatic · Lymphoid

#Lymphoid#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

TQB2102 with TQB2868 (TQB2102 with TQB2868)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
AntibodystaleMacroGenicsPhase 3

Tebotelimab (Tebotelimab)

Gastric Cancer; Gastroesophageal Junction Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 62.5%임상시험 2상태 DISCONTINUED
AntibodystaleBeiGenePhase 2

atezolizumab (Tecentriq, Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab)

Extensive Stage Lung Small Cell Cancer · Extensive Stage Lung Small Cell Cancer

#ExtensiveStageLungSmallCellCance#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodyBiologicstaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
CGTBiologicstaleShanghai Xiniao Biotech Co., Lt…Phase 1

UCAR T-cell group (UCAR T-cell group)

Systemic Lupus Erythematosus · Myasthenia Gravis

#MyastheniaGravis#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
AntibodystaleRochePhase 1

trastuzumab (Herceptin, US sourced Herceptin®)

Healthy · Healthy

#Healthy#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 ACTIVE
CGTBiologicstaleAvenCell Europe GmbHPhase 1

IMP (UniCAR02-T, UniCAR02-T (IMP))

Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 2상태 DISCONTINUED
ADCBiologicstaleGruppo Oncologico del Nord-OvestPhase 2

Vorbipiprant (Vorbipiprant)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
CGTBiologicstaleWugen, Inc.Phase 2

WU-CART-007 (WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 ACTIVE
AntibodystaleXencor, Inc.Phase 2

XmAb18087 (XmAb18087)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 1

XmAb541 (XmAb541)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, YL201 and atezolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
CGTBiologicstaleInge Marie SvanePhase 2

Young TIL (Young TIL)

Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer · Advanced Non-Small Cell Lung Cancer

#AdvancedNon-SmallCellLungCancer#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 33.3%임상시험 2상태 RECRUITING
AntibodystaleGenmabPhase 2

Zalutumumab (Zalutumumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 1

[111In]-FPI-2107 ([111In]-FPI-2107)

Advanced Solid Tumor; Metastatic Colorectal Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
AntibodystaleAmgenPhase 1

acapatamab (acapatamab)

Metastatic Castration-resistant Prostate Cancer; Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#Antibody#Phase1#항체#면역항체+3
임상시험 2상태 DISCONTINUED
AntibodystaleAbbViePhase 3

D2E7 (adalimumab, adalimumab (D2E7))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleAbbViePhase 1

adalimumab (Humira, adalimumab-EU source)

Healthy · Healthy

#Healthy#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 ACTIVE
CGTBiologicstaleKecellitics Biotech Company LtdPhase 1

anti-CD19 CAR (anti-CD19 CAR)

Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 94%임상시험 2상태 ACTIVE

73 / 209 페이지

← 이전다음 →